Daily Stock Analysis, EPIX, ESSA Pharma Inc, priceseries

ESSA Pharma Inc. Daily Stock Analysis
Stock Information
Open
3.73
Close
3.55
High
3.83
Low
3.55
Previous Close
3.75
Daily Price Gain
-0.20
YTD High
4.50
YTD High Date
Jan 22, 2019
YTD Low
2.09
YTD Low Date
Jan 3, 2019
YTD Price Change
1.45
YTD Gain
69.05%
52 Week High
5.83
52 Week High Date
May 2, 2018
52 Week Low
1.87
52 Week Low Date
Dec 31, 2018
52 Week Price Change
-0.27
52 Week Gain
-7.07%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 14. 2017
48.80
Mar 24. 2017
56.31
8 Trading Days
15.40%
Link
LONG
Aug 11. 2017
7.20
Aug 16. 2017
8.10
3 Trading Days
12.50%
Link
LONG
Sep 6. 2017
6.40
Sep 11. 2017
7.00
3 Trading Days
9.37%
Link
LONG
May 1. 2018
4.74
May 2. 2018
5.29
1 Trading Days
11.50%
Link
LONG
Aug 31. 2018
3.25
Sep 6. 2018
3.41
3 Trading Days
5.00%
Link
LONG
Jan 8. 2019
2.64
Jan 29. 2019
3.84
14 Trading Days
45.16%
Link
Company Information
Stock Symbol
EPIX
Exchange
NasdaqCM
Company URL
http://www.essapharma.com
Company Phone
781-761-7600
CEO
David R. Parkinson
Headquarters
Massachusetts
Business Address
4 MAGUIRE ROAD, LEXINGTON, MA 02421
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001027702
About

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It focuses on developing novel and proprietary therapies for the treatment of castration resistant prostate cancer (CRPC) in patients whose disease is progressing despite treatment with current therapies. ESSA Pharma's product candidate, EPI-506, expands the interval of time in which patients suffering from CRPC. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Description

ESSA Pharma Inc., a clinical-stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.